Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Scicinski

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapyRandolph M Johnson, Songnan Wang, Jacqueline A Carozza, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Cell Reports. Medicine|September 6, 2025
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapySongnan Wang, Randolph M Johnson, Jacqueline A Carozza, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Biorxiv : the Preprint Server for Biology|June 6, 2025
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapyRandolph M Johnson, Songnan Wang, Jacqueline A Carozza, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Cell Reports. Medicine|September 6, 2025
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapySongnan Wang, Randolph M Johnson, Jacqueline A Carozza, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Pageof 5